Glaxosmithkline not to pursue further worldwide development of Simplirix
GlaxoSmithKline PLC, a research-based pharmaceutical and healthcare company, said Thursday that it has made the decision not to pursue further worldwide development of Simplirix Herpes Simplex Vaccine, an experimental vaccine intended to prevent genital herpes disease in women.
After knowingly selling drugs with questionable safety for years, drug maker GlaxoSmithKline has agreed to a $750 million settlement.